Huahai US

Huahai US is the North American subsidiary of Zhejiang Huahai Pharmaceutical, a prominent global player in the manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates primarily through its commercial arm, Solco Healthcare, providing a broad portfolio of generic prescription medications to the United States market. Huahai US leverages its parent company's extensive, vertically integrated manufacturing infrastructure to ensure a reliable supply of high-quality, cost-effective medicines. Its therapeutic focus includes cardiovascular health, central nervous system disorders, and anti-viral treatments. As a pioneer in the industry, it was among the first Chinese pharmaceutical firms to achieve large-scale FDA approval for finished dosage products sold in America.